Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
0.3610
Nov 12 • 4:00 PM ET Dollar change-0.0344 Percentage change(-8.70%)
Aftermarket Close
0.3588
Aftermarket • 5:33 PM ET Dollar change-0.0022 Percentage change(-0.61%)
Nov 10, 1:02 PMShareholders approve Evogene-Pure Capital cooperation, lifting stock 30% midday
Index
-
Market Cap
6.52M
Enterprise Value
8.33M
Income
-9.07M
Sales
1.31M
Book/sh
-0.24
Cash/sh
0.52
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
52
IPO
Mar 05, 2008
P/E
-
Forward P/E
-
PEG
-
P/S
4.98
P/B
-
P/C
0.70
P/FCF
-
EV/EBITDA
-
EV/Sales
6.36
Quick Ratio
3.54
Current Ratio
3.57
Debt/Eq
-
LT Debt/Eq
-
Option/Short
No / No
EPS (ttm)
-0.91
EPS next Y
-0.60
EPS next Q
-0.19
EPS this Y
-2.08%
EPS next Y
45.45%
EPS next 5Y
25.25%
EPS past 3/5Y
44.96% 33.52%
Sales past 3/5Y
32.01% 29.94%
EPS Y/Y TTM
59.44%
Sales Y/Y TTM
-80.59%
EPS Q/Q
76.53%
Sales Q/Q
-60.75%
Insider Own
36.98%
Insider Trans
23.28%
Inst Own
1.98%
Inst Trans
4.40%
ROA
-71.03%
ROE
-
ROIC
-
Gross Margin
-14.15%
Oper. Margin
-1019.82%
Profit Margin
-694.19%
SMA20
0.37%
SMA50
-12.54%
SMA200
-42.90%
Trades
Shs Outstand
13.54M
Shs Float
11.38M
52W High
1.28 -71.80%
52W Low
0.25 44.23%
Volatility
21.46% 10.21%
ATR (14)
0.05
RSI (14)
47.75
Beta
1.43
Rel Volume
0.03
Avg Volume
1.42M
Volume
49,010
Perf Week
9.53%
Perf Month
-4.87%
Perf Quarter
-39.91%
Perf Half Y
-51.45%
Perf YTD
-67.18%
Perf Year
-71.12%
Perf 3Y
-93.61%
Perf 5Y
-98.60%
Perf 10Y
-99.39%
Prev Close
0.40
Price
0.36
Change %
-8.70%
Consensus
Strong Buy
Avg. Price Target
$2.15
Implied Upside
+495.6%
Analysts4incl. previous ratings
Rating Distribution4 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Oct 08, 2021Initiated
RROTH Capital
Buy$7+1,839.1%
Jul 29, 2021Initiated
AAegis Capital
Buy$10+2,670.1%
Dec 01, 2020Initiated
CCantor Fitzgerald
Overweight$9+2,393.1%
Dec 16, 2013Initiated
OPY logoOOppenheimer
Outperform$26+7,102.2%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Tarcic GabiChief Development OfficerJun 04 '26Buy0.601,1296771,129Aug 26 04:00 PM
RECANATI LEONDirectorAug 11 '26Buy0.64460,000292,1001,343,886Aug 13 07:00 AM
RECANATI LEONDirectorAug 04 '26Buy0.50800,000400,000883,886Aug 05 04:07 PM
Evogene Ltd. engages in the development and commercialization of a computer-biological platform for improving the development processes of products in the field of life sciences. It operates through the following segments: Agriculture, Industrial Applications, and Human Health. The Agriculture segment develops seed traits, agrochemical products, and agro biological products to improve plant performance. The Industrial Applications focuses on the development and commercialization of improved castor bean seeds for industrial uses. The Human Health segment involves discovery and development of human microbiome-based therapeutics. The company was founded by Amir Barzilay and Hagai Karchi on October 10, 1999 and is headquartered in Rehovot, Israel.
CEOMr. Ofer Haviv CPA
Chief Executive Officer of Casterra Ag Ltd.Mr. Yoash Zohar
Chief Executive Officer of Ag Plenus Ltd.Dr. Dan Jacob Gelvan Ph.D.
Chief Technology OfficerDr. Ilia Zhidkov
Vice President of Human ResourcesMs. Liat Foigel Wejgman